Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Managing Alcoholism in People Who Do Not Respond to Naltrexone (EXTEND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00115037
Recruitment Status : Completed
First Posted : June 21, 2005
Results First Posted : September 18, 2019
Last Update Posted : September 18, 2019
Sponsor:
Information provided by (Responsible Party):
David Oslin, University of Pennsylvania

Brief Summary:
This is a study involving treatment for alcohol dependence (alcoholism). The study will combine motivational enhancement therapy and cognitive behavioral therapy (combined behavioral intervention, or CBI) and tests the benefits of continued/discontinued treatment with naltrexone in a randomized placebo-controlled trial. CBI may have advantages in motivating patients to greater medication adherence and may address psychosocial factors that may limit the effects of naltrexone.

Condition or disease Intervention/treatment Phase
Alcoholism Drug: Naltrexone Drug: placebo Behavioral: Medication Management (MM) Behavioral: Combined Behavioral Intervention (CBI) Behavioral: Telephone Counseling Phase 4

Detailed Description:
Naltrexone has been established as an efficacious medication to treat alcohol dependence but studies thus far have focused mostly on the acute phase of treatment rather than long-term management and have not offered alternative treatment strategies when patients do not respond to an initial course of naltrexone. For these initial non-responders to naltrexone, it is unclear what adjustments to treatment should be made to increase the likelihood of treatment success. We are unaware of previous research focused specifically on naltrexone non-response. Pilot data from ongoing trials at our center, however, suggest that up to a third of patients fail to respond to naltrexone. Moreover, these non-responsive patients go on to have the worst outcomes during the next 6 months of treatment if maintained on the same combination of naltrexone and medication management (MM). We propose to augment medication management with a combination of motivational enhancement therapy and cognitive behavioral therapy (combined behavioral intervention - CBI) and to test the benefits of continued/discontinued treatment with naltrexone in a randomized placebo-controlled trial. Clinical strategies for second line treatments often favor switching treatments rather than augmentation. However, there may be synergies between naltrexone and CBI that were not apparent with medication management. Specifically, CBI may have advantages in motivating patients to greater medication adherence (a leading cause of naltrexone treatment failure) and CBI may address psychosocial factors that limited or attenuated the effects of naltrexone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 302 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Non-Response to Naltrexone (NTX): Next Steps in Managing Alcoholism
Study Start Date : September 2003
Actual Primary Completion Date : April 2008
Actual Study Completion Date : July 2008

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Phase 1 Liberal Response
From the start of baseline subjects were randomly assigned to this arm which defined relapse/non-responder as having 5 or heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
Drug: Naltrexone
100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
Other Name: ReVia

Experimental: Phase 1 Stringent Response
From the start of baseline subjects were randomly assigned to this arm which defined relapse/non-responder as having 2 or heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
Drug: Naltrexone
100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
Other Name: ReVia

Experimental: Phase 2 nalt and tele for responders
Phase 2: Naltrexone and telephone counseling for responders.
Drug: Naltrexone
100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
Other Name: ReVia

Behavioral: Telephone Counseling
Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.

Experimental: Phase 2 nalt, MM and CBI for NR
Phase 2: naltrexone, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR).
Drug: Naltrexone
100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
Other Name: ReVia

Behavioral: Medication Management (MM)
Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
Other Name: MM

Behavioral: Combined Behavioral Intervention (CBI)
45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.
Other Name: CBI

Placebo Comparator: Phase 2 placebo, MM and CBI for NR
Phase 2: placebo, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR)
Drug: placebo
placebo comparer for 16 weeks in phase 2.
Other Name: placebo pill

Behavioral: Medication Management (MM)
Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
Other Name: MM

Behavioral: Combined Behavioral Intervention (CBI)
45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.
Other Name: CBI

Experimental: Phase 2 naltrexone for responders
Phase 2: Naltrexone and TAU for phase 1 responders.
Drug: Naltrexone
100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
Other Name: ReVia




Primary Outcome Measures :
  1. Count of Responders and Non-responders in Phase 1 [ Time Frame: 8 weeks ]
    This is the number of patients who responded to phase 1 treatment based on the definition that subjects were randomly assigned to.

  2. Percentage of Heavy Drinking Days [ Time Frame: 16 weeks ]
    Percentage of days with heavy drinking, where heavy drinking is 4 (5) or more drinks for females (males) in a 24 hour period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Current DSM-IV diagnosis of alcohol dependence using the MINI.
  • Meets the following drinking criteria as measured by the Timeline Followback (TLFB): * drank within 30 days of randomization; * reports a minimum of 48 standard alcoholic drinks (avg. 12 drinks/wk.) in a consecutive 30-day period over the 90-day period prior to intake; and * has 2 or more days of heavy drinking (defined as over 5 drinks per day in males and over 4 drinks per day in females) in this same pre-treatment period, prior to intake.
  • Prior to starting NTX, scores below 8 on the Clinical Inventory of Withdrawal from Alcohol (CIWA), and at least 3 consecutive days of abstinence (2 days abstinence will be permitted with approval by the principal investigator) directly prior to randomization, as determined by Subject report and breathalyzer measures
  • Speaks, understands and prints in English.

Exclusion Criteria:

  • Has abused or been dependent on opiates in the past 12 months, or evidence of opiate use in month prior to treatment, as assessed by subject report and intake urine drug screen. Use of prescription opioids prior to treatment entry is allowed at the discretion of the investigator. However, subjects must be free from use at the time of randomization.
  • Meets DSM IV criteria for current dependence, abuse, or dependence in partial remission on any substance other than alcohol (except nicotine and marijuana). Subjects who test positive on the urine drug screen (with the exception of THC) at the initial visit (a repeat UDSis permitted in cases that are not clear. The repeat UDS should be at least 5 days after the initial test)
  • Has a lifetime DSM-IV diagnosis of schizophrenia or any psychotic disorder. Has a current DSM-IV diagnosis of post-traumatic stress disorder (PTST) or bipolar disorder, or any disorder that may interfere with study participation, at the discretion of the investigator.
  • Hepatocellular disease indicated by elevations of SGPT (ALT) and SGOT (AST) of at least 5 times normal, or elevated bilirubin (of 1.3 or higher), as evidenced by the most recent lab results prior to randomization. (documentation of Gilberts syndrome will not constitute an exclusion despite elevated bilirubin).
  • Has evidence of significant hematological, pulmonary, endocrine, cardiovascular, renal or gastrointestinal disease that the principal investigator considers a risk to participation.
  • Has taken any psychotropic medications (or disulfiram) regularly within the last seven days prior to randomization or needs immediate treatment with a psychotropic medication (with the exception of detoxification medications or benadryl used sparingly for sleep). The required washout period for fluoxetine (Prozac®) is 14 days prior to randomization, and the required washout period for other psychotropic medications is 7 days prior to randomization.
  • Has taken any detoxification medication on the day of randomization.
  • Tests positive on a pregnancy test, is contemplating pregnancy in the next 12 months, is nursing, or is not using an effective contraceptive method if the subject is of child-bearing potential.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00115037


Locations
Layout table for location information
United States, Pennsylvania
University of Pennsylvania Treatment Research Center, Chestnut Street
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
Investigators
Layout table for investigator information
Principal Investigator: David W. Oslin, M.D. University of Pennsylvania
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: David Oslin, Professor, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00115037    
Other Study ID Numbers: NIAAAOSL014851, 708534
First Posted: June 21, 2005    Key Record Dates
Results First Posted: September 18, 2019
Last Update Posted: September 18, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by David Oslin, University of Pennsylvania:
Alcoholism
alcohol abuse
therapy
drug resistance
naltrexone
patient care management
human subject
Additional relevant MeSH terms:
Layout table for MeSH terms
Alcoholism
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Naltrexone
Alcohol Deterrents
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents